Brian Dorsey Sells 25,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey sold 25,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total transaction of $307,500.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $74,095.20. This trade represents a 80.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY opened at $11.90 on Friday. ARS Pharmaceuticals, Inc. has a 52 week low of $5.02 and a 52 week high of $18.51. The company’s fifty day moving average is $14.62 and its 200-day moving average is $12.34. The company has a market capitalization of $1.16 billion, a PE ratio of -23.33 and a beta of 0.88.

Wall Street Analyst Weigh In

SPRY has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $24.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new position in ARS Pharmaceuticals during the 2nd quarter worth about $87,000. Quarry LP acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $174,000. Finally, TFG Advisers LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $180,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.